ArticleUrology2025
Cannabis Use is Associated With Lower Urinary Tract Symptoms in Pediatric Patients-A Large Claims Database Study.
Article in Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate whether cannabis use disorder (CUD) is associated with the diagnosis of lower urinary tract symptoms (LUTS) in pediatric patients.
methodsThis retrospective cohort study queried the TriNetX Research Network for male and female patients under 18 years of age with or without CUD. Propensity score matching was conducted for demographic factors and comorbidities associated with LUTS. The primary outcomes were new diagnoses of all-cause LUTS, pelvic pain, overactive bladder, dysuria, or urinary tract infection (UTI) among patients with CUD compared to controls.
resultsWe identified 4,859,819 male (12,099 CUD, 4,847,720 control) and 4,274,461 female (12,349 CUD, 4,262,112 control) patients for inclusion. After propensity score matching, there were 11,840 male and 11,810 female patients in each arm with median ages of 15.6 and 15.5 years, respectively. At 5-year follow-up, significant increases in new diagnoses of pelvic pain (odds ratios [OR] 2.3 [95% confidence intervals [CI] 1.8-2.9], P <.01), overactive bladder (OR 1.6 [95% CI 1.9-2.7], P <.01), dysuria (OR 1.2 [95% CI 1.1-1.5], P = .01), and UTI (OR 1.8 [95% CI 1.5-2.1], P <.01) were observed among female CUD patients compared to controls. At 5-year follow-up, significant increases in new diagnoses of pelvic pain (OR 3.8 [95% CI 2.4-5.9], P <.01), dysuria (OR 1.4 [95% CI 1.1-1.8], P = .02), and UTI (OR 1.7 [95% CI 1.2-2.6], P <.01) were observed in male CUD patients compared to controls.
conclusionWe observed significant increases in first-time LUTS diagnoses in pediatric patients with CUD compared to matched controls. Further research into cannabinoids' impact on urinary tract and pelvic floor function is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.